Trial Profile
Immunogenicity and Safety of ChimeriVaxTetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary) ; Meningococcal vaccine groups A and C polysaccharide; Typhoid vaccine Vi-polysaccharide
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 05 Feb 2013 Planned end date changed from 1 Jul 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 03 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Apr 2009 New trial record